ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VNDA Vanda Pharmaceuticals Inc

4.97
0.29 (6.20%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vanda Pharmaceuticals Inc NASDAQ:VNDA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.29 6.20% 4.97 3.75 6.49 4.91 4.7001 4.71 681,346 05:00:08

Statement of Changes in Beneficial Ownership (4)

14/06/2021 9:38pm

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Watkins Thomas
2. Issuer Name and Ticker or Trading Symbol

Vanda Pharmaceuticals Inc. [ VNDA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

1221 GULF SHORE BLVD N #303
3. Date of Earliest Transaction (MM/DD/YYYY)

6/10/2021
(Street)

NAPLES, FL 34102
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 6/10/2021  A  5000 (1)A$0.00 54505 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $19.21 6/10/2021  A   10000     (2)6/9/2031 Common Stock 10000 $0.00 10000 D  

Explanation of Responses:
(1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
(2) This option vests and becomes exercisable with respect to 100% of the option shares on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Watkins Thomas
1221 GULF SHORE BLVD N #303
NAPLES, FL 34102
X



Signatures
/s/ H. Thomas Watkins6/12/2021
**Signature of Reporting PersonDate

1 Year Vanda Pharmaceuticals Chart

1 Year Vanda Pharmaceuticals Chart

1 Month Vanda Pharmaceuticals Chart

1 Month Vanda Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock